BPA Call 36C25723A0025-36C25726N0252

Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division, received a $52.2K firm fixed-price Blanket Purchase Agreement (BPA) call from Veterans Integrated Service Network 17 (VISN 17), a Veterans Affairs civilian agency component, for Oncotype DX gene expression profiling services. The contract award was issued on June 5, 2026, with an ultimate completion date of June 4, 2027, and was performed at the contractor's facility in Temple, Texas. This award was not issued under a set-aside designation, reflecting Exact Sciences' established competitive position as a specialized provider of proprietary oncology diagnostic testing services. The underlying vehicle is the Medical Laboratory Testing and Analysis Services (FSS-621-II) General Services Administration General Schedule contract, which enables federal agencies to procure specialized medical laboratory services.

Exact Sciences Corporation has a well-established presence across the Department of Veterans Affairs, holding multiple blanket purchase agreements with various Veterans Integrated Service Networks for Oncotype DX testing, including a $4M single-award BPA with VISN 17 through August 2028. The company specializes in advanced genomic and molecular diagnostic testing for cancer screening, detection, and treatment planning, with its Oncotype DX assays analyzing gene expression profiles to assess recurrence risk and predict treatment responsiveness for breast, prostate, and colorectal cancers. Beyond the VA, Exact Sciences maintains significant federal contract relationships with the Defense Health Agency, Army Medical Command, and Air Force organizations, demonstrating sustained demand for its specialized oncology diagnostic capabilities across the federal healthcare system.